+

RU2006113366A - Терапевтическое лечение - Google Patents

Терапевтическое лечение Download PDF

Info

Publication number
RU2006113366A
RU2006113366A RU2006113366/15A RU2006113366A RU2006113366A RU 2006113366 A RU2006113366 A RU 2006113366A RU 2006113366/15 A RU2006113366/15 A RU 2006113366/15A RU 2006113366 A RU2006113366 A RU 2006113366A RU 2006113366 A RU2006113366 A RU 2006113366A
Authority
RU
Russia
Prior art keywords
combination according
prevention
atherosclerosis
treatment
pharmaceutically acceptable
Prior art date
Application number
RU2006113366/15A
Other languages
English (en)
Other versions
RU2358737C2 (ru
Inventor
Джей Лал МЕХТА (US)
Джей Лал МЕХТА
Original Assignee
АстраЗенека Ю-Кей Лимитед (GB)
АстраЗенека Ю-Кей Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АстраЗенека Ю-Кей Лимитед (GB), АстраЗенека Ю-Кей Лимитед filed Critical АстраЗенека Ю-Кей Лимитед (GB)
Publication of RU2006113366A publication Critical patent/RU2006113366A/ru
Application granted granted Critical
Publication of RU2358737C2 publication Critical patent/RU2358737C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)

Claims (11)

1. Комбинация, содержащая кандесартан или его фармацевтически приемлемую соль и розувастатин или его фармацевтически приемлемую соль, для предупреждения или лечения атеросклероза.
2. Фармацевтическая композиция, содержащая комбинацию по п.1 вместе с фармацевтически приемлемым разбавителем или носителем, для применения в предупреждении или лечении атеросклероза.
3. Фармацевтическая композиция, содержащая комбинацию по п.1 вместе с фармацевтически приемлемым разбавителем или носителем, для применения в предупреждении сердечно-сосудистых событий.
4. Комбинация по п.1 для применения в изготовлении лекарства для предупреждения или лечения атеросклероза.
5. Комбинация по п.1 для применения в изготовлении лекарства для предупреждения сердечно-сосудистых событий.
6. Комбинация по п.1 для применения в качестве лекарственного средства для предупреждения или лечения атеросклероза.
7. Комбинация по п.1 для применения в качестве лекарственного средства для предупреждения сердечно-сосудистых событий.
8. Способ предупреждения или лечения атеросклероза у теплокровного животного, например человека, включающий введение комбинации по п.1.
9. Способ предупреждения сердечно-сосудистых событий у теплокровного животного, например человека, включающий введение комбинации по п.1.
10. Набор, включающий комбинацию по п.1, возможно, с инструкциями по применению в предупреждении или лечении атеросклероза.
11. Комбинация по п.1, в которой кандесартан находится в форме кандесартана цилексетила.
RU2006113366/15A 2003-09-26 2004-09-22 Терапевтическое лечение RU2358737C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0322552.1 2003-09-26
GBGB0322552.1A GB0322552D0 (en) 2003-09-26 2003-09-26 Therapeutic treatment

Publications (2)

Publication Number Publication Date
RU2006113366A true RU2006113366A (ru) 2007-11-10
RU2358737C2 RU2358737C2 (ru) 2009-06-20

Family

ID=29286881

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006113366/15A RU2358737C2 (ru) 2003-09-26 2004-09-22 Терапевтическое лечение

Country Status (29)

Country Link
US (2) US7932263B2 (ru)
EP (1) EP1673091B1 (ru)
JP (1) JP4841433B2 (ru)
KR (1) KR101129767B1 (ru)
CN (1) CN100515421C (ru)
AT (1) ATE451103T1 (ru)
AU (1) AU2004275567B2 (ru)
BR (1) BRPI0414724A (ru)
CA (1) CA2540102C (ru)
CY (1) CY1109814T1 (ru)
DE (1) DE602004024555D1 (ru)
DK (1) DK1673091T3 (ru)
ES (1) ES2336450T3 (ru)
GB (1) GB0322552D0 (ru)
HK (1) HK1090553A1 (ru)
HR (1) HRP20100080T1 (ru)
IL (1) IL174536A (ru)
IS (1) IS2729B (ru)
MX (1) MXPA06003353A (ru)
NO (1) NO335813B1 (ru)
NZ (1) NZ546162A (ru)
PL (1) PL1673091T3 (ru)
PT (1) PT1673091E (ru)
RU (1) RU2358737C2 (ru)
SG (1) SG145773A1 (ru)
SI (1) SI1673091T1 (ru)
UA (1) UA90249C2 (ru)
WO (1) WO2005030215A2 (ru)
ZA (1) ZA200602433B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
US9260708B2 (en) * 2009-09-29 2016-02-16 Butamax Advanced Biofuels Llc Yeast production host cells
US20120239131A1 (en) * 2011-03-15 2012-09-20 Medtronic Vascular, Inc. Methods and apparatus for treatment of aneurysmal tissue
EP2787993B1 (en) * 2011-12-09 2016-11-23 Artskin D.O.O. TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
CN103479627A (zh) * 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
KR101771766B1 (ko) 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
MX2019005572A (es) * 2016-11-15 2019-08-14 Lg Chemical Ltd Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica.

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US6004989A (en) 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
ATE220333T1 (de) 1996-04-05 2002-07-15 Takeda Chemical Industries Ltd Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin- sensitivität erhöht
EP0930076B1 (en) * 1996-07-15 2004-12-01 Sankyo Company Limited Pharmaceutical compositions comprising CS-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma
JPH1081633A (ja) 1996-07-16 1998-03-31 Sankyo Co Ltd 医薬組成物
KR20010022385A (ko) 1997-08-29 2001-03-15 실버스타인 아써 에이. 암로디핀 및 스타틴 화합물을 포함하는 복합 조성물
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AR022462A1 (es) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
IL145773A0 (en) 1999-04-13 2002-07-25 Basf Ag Integrin receptor ligands
IL148127A0 (en) 1999-08-30 2002-09-12 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
CA2381926A1 (en) 1999-08-31 2001-03-08 Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
AR030414A1 (es) 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
CN1651087A (zh) * 2000-04-12 2005-08-10 诺瓦提斯公司 有机化合物的联合形式
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2002017913A1 (fr) * 2000-08-30 2002-03-07 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
JP2002145770A (ja) 2000-08-30 2002-05-22 Sankyo Co Ltd 心不全の予防又は治療のための医薬組成物
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
MXPA03006729A (es) * 2001-01-26 2003-10-24 Schering Corp Utilizacion de compuestos de azetidinona sustituida para el tratamiento de la sitosterolemia.
AR032643A1 (es) 2001-01-26 2003-11-19 Schering Corp Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares
US20030053950A1 (en) * 2001-04-18 2003-03-20 Mcgill University Individualization of therapy with hyperlipidemia agents
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
WO2004096810A1 (en) * 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
JP2005126338A (ja) 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20060078615A1 (en) 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin

Also Published As

Publication number Publication date
IS8421A (is) 2006-04-21
PL1673091T3 (pl) 2010-04-30
JP2007506720A (ja) 2007-03-22
NO20061744L (no) 2006-06-22
IL174536A0 (en) 2008-04-13
DK1673091T3 (da) 2010-03-22
ZA200602433B (en) 2007-06-27
RU2358737C2 (ru) 2009-06-20
IS2729B (is) 2011-04-15
MXPA06003353A (es) 2006-06-08
WO2005030215A2 (en) 2005-04-07
CN100515421C (zh) 2009-07-22
CY1109814T1 (el) 2014-09-10
IL174536A (en) 2010-12-30
ES2336450T3 (es) 2010-04-13
CN1886136A (zh) 2006-12-27
SG145773A1 (en) 2008-09-29
EP1673091A2 (en) 2006-06-28
ATE451103T1 (de) 2009-12-15
EP1673091B1 (en) 2009-12-09
JP4841433B2 (ja) 2011-12-21
GB0322552D0 (en) 2003-10-29
US20070275989A1 (en) 2007-11-29
KR101129767B1 (ko) 2012-03-26
UA90249C2 (ru) 2010-04-26
WO2005030215A3 (en) 2005-06-02
CA2540102C (en) 2012-07-24
US20110046119A1 (en) 2011-02-24
BRPI0414724A (pt) 2006-11-21
KR20060108623A (ko) 2006-10-18
PT1673091E (pt) 2010-02-15
HK1090553A1 (en) 2006-12-29
HRP20100080T1 (hr) 2010-04-30
NO335813B1 (no) 2015-02-23
DE602004024555D1 (de) 2010-01-21
SI1673091T1 (sl) 2010-03-31
US7932263B2 (en) 2011-04-26
NZ546162A (en) 2008-11-28
CA2540102A1 (en) 2005-04-07
AU2004275567A1 (en) 2005-04-07
AU2004275567B2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
TNSN06034A1 (en) Pyridazine derivatives and their use as therapeutic agents
RU2006113366A (ru) Терапевтическое лечение
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
SE0401342D0 (sv) Therapeutic compounds
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
GB0130677D0 (en) Medicaments and novel compounds
NO20054714L (no) Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom
EA200000176A1 (ru) Применение физиологически приемлемых соединений, солей и комплексов ванадия
EA200800075A1 (ru) Схема дозирования для празугреля
EA200801305A1 (ru) Применение циклетанина и других фуропиридинов для лечения гипертензии с преобладанием систолического давления, изолированной систолической гипертензии, повышенного пульсового артериального давления и общей гипертензии
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
GEP201606538B (en) Preoperative treatment of post operative pain
RU2005131578A (ru) Аплидин для лечения множественной миеломы
DE60204694D1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
HUP0401798A2 (hu) Rosuvastatin alkalmazása demencia előtti állapotokban használható gyógyszerkészítmény előállítására
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160923

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载